We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Exhaled Nitrous Oxide Adjunct Test Diagnoses Asthma

By LabMedica International staff writers
Posted on 04 Jan 2018
Although about 24 million Americans are diagnosed with asthma every year, there is no single test that can diagnose the disease and common symptoms, such as shortness of breath, wheezing, and cough, are relatively nonspecific.

Various tests, including bronchodilator response and positive results on bronchial challenge, may be used by clinicians to aid in the diagnosis of asthma in the appropriate clinical context, but no single criterion standard diagnostic test exists. More...
More recently, fractional exhaled nitric oxide (FeNO) concentration has been added to the list of tests that clinicians may use to diagnose asthma.

A team of scientists from the Mayo Clinic (Rochester, MN, USA) conducted a comprehensive literature search of six databases. The search included randomized clinical trials and observational studies that (1) enrolled patients aged five years and older with suspected asthma, (2) compared FeNO testing (diagnostic test) to standard diagnostic testing of asthma by health care professionals based on history, clinical course, or other diagnostic tests (clinical diagnosis, bronchodilator response, and positive results on bronchial challenge) (reference test), and (3) reported FeNO diagnostic accuracy.

The team included 43 studies with a total of 13,747 patients. In adults, using FeNO cutoffs of less than 20, 20 to 29, 30 to 39, and 40 or more parts per billion (ppb), FeNO testing had sensitivities of 0.80, 0.69, 0.53, and 0.41, respectively, and specificities of 0.64, 0.78, 0.85, and 0.93, respectively. In children, using FeNO cutoffs of less than 20 and 20 to 29 ppb, FeNO testing had sensitivities of 0.78 and 0.61, respectively, and specificities of 0.79 and 0.89, respectively. Depending on the FeNO cutoff, the posttest odds of having asthma with a positive FeNO test result increased by 2.80-fold to 7.00-fold. Diagnostic accuracy was modestly better in corticosteroid-naive asthmatics, children, and nonsmokers than in the overall population.

M. Hassan Murad, MD, MPH, the lead investigator of the study, said, “Asthma can sometimes be difficult to diagnose, and FeNO can be helpful to make therapeutic decisions more evidence based. In addition to a patient's history, the initial test is usually spirometry with an assessment of bronchodilator response. If this test does not confirm the diagnosis, but the index of suspicion for asthma is still high, measurement of FeNO may be helpful to rule in disease; although will still miss some patients with asthma.” The study was published on December 20, 2017, in the journal Mayo Clinic Proceedings.

Related Links:
Mayo Clinic


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.